NEW YORK – Natera recently provided updates on the development of its Signatera cancer and Prospera organ transplant assays, both cell-free DNA tests, as well as on a number of legal proceedings it is part of, including three patent lawsuits and two suits filed by patients.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.